Organisation paid for research Program year 2025 Source: CMS Open Payments

Atlanta Center for Medical Research

Neither a doctor nor a teaching hospital

Research payments

$52,406,894

3,305 payments

Through program year 2025, Atlanta Center for Medical Research is reported as receiving $52,406,894 in research payments, across 3,305 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $6,052,988 758
2024 Research $6,179,346 396
2023 Research $14,884,238 544
2022 Research $3,288,966 218
2021 Research $5,593,486 357
2020 Research $8,879,315 462
2019 Research $7,528,554 570

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vertex Pharmaceuticals Incorporated $11,446,682 19 payments
  2. Allergan Inc. $9,258,389 607 payments
  3. Teva Pharmaceuticals USA, Inc. $8,371,099 389 payments
  4. ITI, Inc. $4,037,419 840 payments
  5. Sunovion Pharmaceuticals Inc. $3,931,155 246 payments
  6. Sumitomo Pharma America, Inc. $2,731,943 242 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $2,486,651 3 payments
  8. Merck Sharp & Dohme Corporation $1,145,204 34 payments
  9. AbbVie, Inc. $935,808 108 payments
  10. Sage Therapeutics, Inc. $917,993 39 payments
Studies the money was for Research payments · program years 2019–2025
  1. Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty $5,384,844 2 payments
  2. A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study with an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients with Schizophrenia $4,680,395 199 payments
  3. A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia $3,184,142 125 payments
  4. Tv44749-Sad-10154 $2,868,607 44 payments
  5. A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment $2,321,878 65 payments
  6. A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder $2,238,450 2 payments
  7. A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy $2,077,280 3 payments
  8. Iti-007-452 $1,772,711 606 payments
  9. Double-Blind, Placebo Controlled, Single and Multiple-Dose Study of Agn-241751 in Adult Participants With Major Depressive Disorder $1,567,060 52 payments
  10. A Phase 3b, Open-label, Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine As Part of Multimodal Therapy for Acute Pain After Aesthetic or Reconstructive Surgeries $1,306,308 2 payments
What the money was spent on Research payments · program years 2019–2025
  1. Overhead $283,725 6 payments
  2. Other $81,492 6 payments
  3. Patient care $71,387 28 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record